Back to search results

Early Heart Screening and Treatment for Sickle Cell Disease

This study is looking at whether early screening and treatment for iron overload can prevent heart problems and reduce hospital stays for people with sickle cell disease. Researchers will use special tests like echocardiography (ultrasound of the heart) and electrocardiograms (ECG, which records heart's electrical activity) to check your heart. If you have too much iron, you might receive iron-reducing medicines like Deferoxamine, Deferasirox, or Deferiprone. To join, you need to be at least 18 years old, have sickle cell disease, and have certain iron levels in your blood. The study aims to see if this approach lowers the number and length of hospitalizations for sickle cell complications over 12 months. The current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 100 participants. The phase of the study is not specified.
What's involved
You would undergo regular imaging (echocardiograms, ECG, cardiac MRI) and lab testing every 3 months for 12 months.
Compensation
Not stated in the trial record.
Follow-up
The primary outcomes, such as hospitalizations, will be measured for up to 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07023666

Early Screening and Treatment of Heart Complication in Sickle Cell Disease

Recruiting
PHASE2Ages 18+InterventionalTreatment
Inova Health Care Services
~100 participants
Updated 2025-10-14 on ClinicalTrials.gov
What's tested:DeferoxamineDeferasiroxDeferiproneEchocardiographyElectrocardiogram (ECG)

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Hospitalization for Sickle Cell Disease Related Complications
Measured over Up to 12 months
+1 more outcome measured

Conditions

Sickle Cell Disease

Explore related trials

Sickle Cell Disease

Where it's being run

2 sites across 1 states
Virginia2

Study leadership

  • Sheinei Alan, MD · PRINCIPAL_INVESTIGATOR · Inova Fairfax Hospital

Who to contact

Keary Jane't
keary.jane'[email protected]
571-472-3173
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

At least 18 years of age
Diagnosis of sickle cell disease (any genotype)
Serum ferritin levels ≥ 400 ng/mL (up to 80 patients), or less than 400 ng/mL in those who have cardiac symptoms including shortness of breath and lower extremity edema (up to 20 patients)
Willingness to undergo regular imaging (echocardiograms, ECG, cardiac MRI)
ECOG performance status of 0-1
Able to read, understand and provide written informed consent
Deemed appropriate for participation by the treating physician

Exclusion

Unable to schedule and required follow-up visits
Medical comorbidities including:
Known heart failure
Unstable angina
Uncontrolled dysrhythmias
Acute pulmonary embolism
Active infection or severe comorbid conditions that in the view of the investigator would limit participation
History of hypersensitivity or contraindication to chelation therapy
Severe renal or hepatic impairment
Pregnancy of breastfeeding

What this trial measures

  • Incidence of Hospitalization for Sickle Cell Disease Related ComplicationsUp to 12 months

    Total number of participants hospitalized for SCD related complications including vaso-occlusive crises, acute chest syndrome and infection detect the impact of early intervention of cardiac iron overload in patients with Sickle Cell Disease

  • Length of Stay for SCD-Related ComplicationsUp to 12 Months

    The total number of days spent in the hospital per admission for complications related to SCD.